Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Baxalta Innovations GmbH

Home Clinical Trial Sponsors and OrganizationsBaxalta Innovations GmbH

Baxalta Innovations GmbH

ACTIVE

Uferstraße 15, Orth An Der Donau, Niederösterreich, Austriawww.baxalta.atSubsidiary

Part of baxalta gmbh

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

155

146 active

Approvals

48

Total approvals

Agencies

3

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

132

85.2%

Phase 3

11

7.1%

Phase 4

2

1.3%

Not Applicable

1

0.7%

Trial Status Distribution

Active, not recruiting

145

93.5%

Completed

1

0.7%

Not yet recruiting

1

0.7%

Recruiting

5

3.2%

Withdrawn

3

1.9%

Clinical Trials

Trials sponsored by this organization (155)

A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the drug TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)

Jun 202475 participants

A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advate for children diagnosed with Severe von Willebrand Disease who experience bleeding episodes and/or will undergo major, minor or oral surgery procedures.

Apr 202427 participants

A study of safety, effect on the immune system and blood clotting of BAX855 (factor VIII of blood clotting) in pediatric patients who have not received treatment for their severe hemophilia A.

Active, not recruiting

A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advate for children diagnosed with Severe von Willebrand Disease who experience bleeding episodes and/or will undergo major, minor or oral surgery procedures.

Active, not recruiting

A Post Marketing Surveillance (PMS) Study of RIXUBIS in India

Active, not recruiting

A study on the long-term safety and effectiveness of rVWF in children and adults diagnosed with Severe von Willebrand Disease.

Active, not recruiting

Jun 202264 participants

A Study of the Safety and Tolerability of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors

Active, not recruiting

May 202232 participants

A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic Thrombocytopenic Purpura (cTTP) with the drug TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)

Active, not recruiting

Dec 202177 participants

Page 1 of 20

Approvals

Approvals by Agency

EMA

European Medicines Agency

12

Approvals

SFDA

Saudi Food and Drug Authority

9

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

27

Approvals

Recent Approvals

CUVITRU 200MG/ML INJECTION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

CUVITRU 200MG/ML INJECTION

CUVITRU 200MG/ML INJECTION

CUVITRU 200MG/ML INJECTION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

HYQVIA 100MG/ML SOLUTION FOR INFUSION

FEIBA 100 U/ML POLVO Y DISOLVENTE PARA SOLUCIÓN PARA PERFUSIÓN

News

No news articles found

On this page

Overview
Clinical Trials155
Approvals48
News

Back to Organizations